These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

728 related items for PubMed ID: 18643839

  • 41. Insulin degludec/insulin aspart versus biphasic insulin aspart 30 twice daily in insulin-experienced Japanese subjects with uncontrolled type 2 diabetes: Subgroup analysis of a Pan-Asian, treat-to-target Phase 3 Trial.
    Taneda S, Hyllested-Winge J, Gall MA, Kaneko S, Hirao K.
    J Diabetes; 2017 Mar; 9(3):243-247. PubMed ID: 27059529
    [Abstract] [Full Text] [Related]

  • 42. Comparison of insulin lispro protamine suspension and insulin detemir in basal-bolus therapy in patients with Type 1 diabetes.
    Chacra AR, Kipnes M, Ilag LL, Sarwat S, Giaconia J, Chan J, COMPLETE T1D investigators.
    Diabet Med; 2010 May; 27(5):563-9. PubMed ID: 20536953
    [Abstract] [Full Text] [Related]

  • 43. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin.
    De Leeuw I, Vague P, Selam JL, Skeie S, Lang H, Draeger E, Elte JW.
    Diabetes Obes Metab; 2005 Jan; 7(1):73-82. PubMed ID: 15642078
    [Abstract] [Full Text] [Related]

  • 44. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial.
    Lund SS, Tarnow L, Frandsen M, Nielsen BB, Hansen BV, Pedersen O, Parving HH, Vaag AA.
    BMJ; 2009 Nov 09; 339():b4324. PubMed ID: 19900993
    [Abstract] [Full Text] [Related]

  • 45. Treat-to-target trials: uses, interpretation and review of concepts.
    Garber AJ.
    Diabetes Obes Metab; 2014 Mar 09; 16(3):193-205. PubMed ID: 23668598
    [Abstract] [Full Text] [Related]

  • 46. Lower rates of hypoglycemia during maintenance treatment with insulin degludec/insulin aspart versus biphasic insulin aspart 30: a combined analysis of two Phase 3a studies in type 2 diabetes.
    Christiansen JS, Niskanen L, Rasmussen S, Johansen T, Fulcher G.
    J Diabetes; 2016 Sep 09; 8(5):720-8. PubMed ID: 26612062
    [Abstract] [Full Text] [Related]

  • 47. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Rosenstock J, Davies M, Home PD, Larsen J, Koenen C, Schernthaner G.
    Diabetologia; 2008 Mar 09; 51(3):408-16. PubMed ID: 18204830
    [Abstract] [Full Text] [Related]

  • 48. Biphasic insulin aspart 30: literature review of adverse events associated with treatment.
    Davidson J, Vexiau P, Cucinotta D, Vaz J, Kawamori R.
    Clin Ther; 2005 Mar 09; 27 Suppl B():S75-88. PubMed ID: 16519039
    [Abstract] [Full Text] [Related]

  • 49. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison.
    Ilag LL, Kerr L, Malone JK, Tan MH.
    Clin Ther; 2007 Mar 09; 29 Spec No():1254-70. PubMed ID: 18046926
    [Abstract] [Full Text] [Related]

  • 50. A 26-week, randomized, parallel, treat-to-target trial comparing insulin detemir with NPH insulin as add-on therapy to oral glucose-lowering drugs in insulin-naive people with type 2 diabetes.
    Hermansen K, Davies M, Derezinski T, Martinez Ravn G, Clauson P, Home P.
    Diabetes Care; 2006 Jun 09; 29(6):1269-74. PubMed ID: 16732007
    [Abstract] [Full Text] [Related]

  • 51. Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes.
    Kølendorf K, Ross GP, Pavlic-Renar I, Perriello G, Philotheou A, Jendle J, Gall MA, Heller SR.
    Diabet Med; 2006 Jul 09; 23(7):729-35. PubMed ID: 16842476
    [Abstract] [Full Text] [Related]

  • 52. Initiation with once-daily BIAsp 30 results in superior outcome compared to insulin glargine in Asians with type 2 diabetes inadequately controlled by oral anti-diabetic drugs.
    Kalra S, Plata-Que T, Kumar D, Mumtaz M, Søndergaard F, Kozlovski P, Bebakar WM.
    Diabetes Res Clin Pract; 2010 Jun 09; 88(3):282-8. PubMed ID: 20363044
    [Abstract] [Full Text] [Related]

  • 53. Once-daily insulin detemir in a cohort of insulin-naïve patients with type 2 diabetes: a sub-analysis from the PREDICTIVE study.
    Meneghini LF, Dornhorst A, Sreenan S, PREDICTIVE Study Group.
    Curr Med Res Opin; 2009 Apr 09; 25(4):1029-35. PubMed ID: 19281426
    [Abstract] [Full Text] [Related]

  • 54. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison.
    Robbins DC, Beisswenger PJ, Ceriello A, Goldberg RB, Moses RG, Pagkalos EM, Milicevic Z, Jones CA, Sarwat S, Tan MH.
    Clin Ther; 2007 Nov 09; 29(11):2349-64. PubMed ID: 18158076
    [Abstract] [Full Text] [Related]

  • 55. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus.
    Janka HU, Plewe G, Busch K.
    J Am Geriatr Soc; 2007 Feb 09; 55(2):182-8. PubMed ID: 17302653
    [Abstract] [Full Text] [Related]

  • 56. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes.
    Shah S, Das AK, Kumar A, Unnikrishnan AG, Kalra S, Baruah MP, Ganapathi B, Sahay RK.
    Adv Ther; 2009 Mar 09; 26(3):325-35. PubMed ID: 19252828
    [Abstract] [Full Text] [Related]

  • 57. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial.
    Davies M, Lavalle-González F, Storms F, Gomis R, AT.LANTUS Study Group.
    Diabetes Obes Metab; 2008 May 09; 10(5):387-99. PubMed ID: 18355327
    [Abstract] [Full Text] [Related]

  • 58. A randomized, treat-to-target trial comparing insulin lispro protamine suspension and insulin detemir in insulin-naive patients with Type 2 diabetes.
    Fogelfeld L, Dharmalingam M, Robling K, Jones C, Swanson D, Jacober S.
    Diabet Med; 2010 Feb 09; 27(2):181-8. PubMed ID: 20546262
    [Abstract] [Full Text] [Related]

  • 59. A comparison of intensive mixture therapy with basal insulin therapy in insulin-naïve patients with type 2 diabetes receiving oral antidiabetes agents.
    Jacober SJ, Scism-Bacon JL, Zagar AJ.
    Diabetes Obes Metab; 2006 Jul 09; 8(4):448-55. PubMed ID: 16776752
    [Abstract] [Full Text] [Related]

  • 60. Starting insulin therapy with basal insulin analog or premix insulin analog in T2DM: a pooled analysis of treat-to-target trials.
    Fonseca V, Davidson J, Home P, Snyder J, Jellinger P, Dyhr Toft A, Barnett A.
    Curr Med Res Opin; 2010 Jul 09; 26(7):1621-8. PubMed ID: 20429817
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.